What is Veritas Aortic Solutions?
Veritas Aortic Solutions operates at the intersection of medical technology and cardiovascular surgery, specializing in minimally invasive therapies for the aortic root and ascending aorta. As a spinout of inQB8 Medical Technologies, the company is currently developing its flagship Transcatheter Valved Aortic Root Conduit (TVARC) technology. This innovation is engineered to provide a non-surgical alternative to traditional open-heart procedures, which are often associated with high morbidity and extended recovery times.
The company's market position is defined by its focus on high-acuity conditions, including aortic aneurysms and dissections. By targeting these complex cardiovascular conditions, Veritas Aortic Solutions aims to improve patient outcomes and reduce the systemic burden of invasive surgical interventions. Its development pipeline reflects a sophisticated approach to structural heart disease, leveraging proprietary conduits to restore aortic function with precision.
How much funding has Veritas Aortic Solutions raised?
Veritas Aortic Solutions has raised a total of $12M across 1 funding round:
Seed
$12M
Seed (2026): $12M with participation from Cedars-Sinai
Key Investors in Veritas Aortic Solutions
Cedars-Sinai
Cedars-Sinai is a premier non-profit academic medical center in the United States, renowned for its extensive clinical programs and commitment to advancing specialized treatments for complex and rare illnesses.
What's next for Veritas Aortic Solutions?
Looking ahead, the strategic deployment of this capital will likely focus on clinical validation and regulatory milestones for the TVARC technology. As the company transitions from its initial development phase toward more rigorous clinical trials, the focus will shift to demonstrating the safety and efficacy of its minimally invasive conduits in human subjects. This phase is critical for establishing the clinical evidence required for regulatory approval and subsequent market adoption.
Furthermore, the company is expected to scale its operational infrastructure to support the manufacturing and distribution requirements of its medical devices. By leveraging its recent financing, Veritas Aortic Solutions is poised to solidify its intellectual property portfolio and expand its clinical partnerships, ensuring that its innovative therapies reach the patients who need them most. The path forward involves navigating the complex regulatory environment while maintaining a focus on long-term clinical excellence.
